Overview

TINN2: Treat Infection in NeoNates 2

Status:
Withdrawn
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of bronchopulmonary dysplasia in preterm neonates.
Phase:
Phase 3
Details
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators:
Advanced Biological Laboratories ABL (ABL SA)
Assistance Publique - Hôpitaux de Paris
Cardiff University
Centre Hospitalier Chrétien (CHC)
Erasmus Medical Center
Heinrich-Heine-Universität Düsseldorf (UDUS)
Inserm-Transfert (IT)
Karolinska Institutet
Mario Negri Institute (IRFMN)
Only For Children Pharmaceuticals
Semmelweis University
Simcyp Limited (SimCyp)
University of Liverpool
University of Nottingham
University of Ulm
Treatments:
Azithromycin